Antidiabetics Market Share Growth Size Trends with Eli Lilly and Company, Merck, Boehringer Ingelheim, Novo Nordisk, Sanofi

U.S. antidiabetics market held largest market share of 87.5% of North America antidiabetics market in 2017. High growth is attributable to elevating cases of diabetes along with robustly rising obese population. Majority of the adult population affected by diabetes mellitus are overweight or obese. Many firms across the U.S. are emphasizing on innovative diabetes medications. Also, growing awareness among the American population regarding diagnosis and treatment of target disease will boost demand for antidiabetics in future.

China antidiabetics market will foresee lucrative growth at 14.6% CAGR during the forecast years. Rising geriatric pool will significantly contribute to growing demand for antidiabetics across the country. Age being one of the major risk factors for the disease, China has one of the largest patient pools with diagnosed diabetes. With ever-increasing elderly population along with growing R&D activities, Chinese antidiabetics business will continue to grow robustly in forthcoming years.

Request for a sample of this research report @ https://www.gminsights.com/request-sample/detail/504

Growing pervasiveness of diabetes worldwide will spur global antidiabetics market growth over the forecast timeframe. According to World Health Organization, in 2014, 422 million people suffered from diabetes mellitus, estimated to become the seventh death-leading cause by 2030. Thus, rising prevalence of the disease will lead to high adoption of antidiabetic drugs to control blood sugar as well as control disease complications. Moreover, accelerating number of obese/overweight people, pursuing unhealthy lifestyle habits is significantly increasing the risk of suffering from diabetes. Growing incidence of diabetes can be attributed to increasing obese population, thereby augmenting demand for antidiabetics in coming years.

Increasing focus on research activities for development of antidiabetics will stimulate antidiabetics business growth during the upcoming years. Adverse events and need for more effective drugs are leading firms to invest more into antidiabetic drugs and antidiabetics delivering devices. For instance, Novo Nordisk is investing heavily on its pipeline drug, Ozempic, for type 2 diabetes in adults. In addition, need for development of affordable drugs, especially in emerging nations will result into huge pipeline portfolio of firms, further offering lucrative industry growth opportunities in the foreseeable future.

Insulin product segment is forecasted to progress at 12.3% CAGR over the projected period. With expanding patient population majorly suffering from type 2 diabetes, the need to administer insulin therapy will grow in the forthcoming years. Insulin is also used in combination with several oral drugs for better control of blood glucose. In addition, insulin also needs to be externally injected to patients with type 1 diabetes, that should impel segmental growth in coming period. Among several types of insulin, rapid acting analog insulin will show fastest growth over the forecast period.

Browse Full Report Details @ https://www.gminsights.com/industry-analysis/antidiabetics-market

Drug class product segment held 45.7% market share in 2017. DPP-IV drug class accounted for the largest revenue size in 2017 and will witness similar trend over the coming years. DPP-IV when combined with other antidiabetic agents are known to show positive effect on glucose control. These drugs show neutral effect on weight that further favours segmental growth. Development of new antidiabetic drugs including DPP-IV will boost segment growth in upcoming years.

Company profiled in this report based on Business overview, Financial data, Product landscape, Strategic outlook & SWOT analysis:
 Novo Nordisk
 Sanofi
 Eli Lilly and Company
 Merck
 Boehringer Ingelheim

Adult patient population segment accounted for largest market share of 51.0% in 2017. With increasing risk factors such as age, obesity, lack of physical activity and rising consumption of carbohydrate-rich food among adult age groups has considerable effect on development of diabetes. According to a recent study, majority of adults in comparison to other age groups are suffering from type 2 diabetes. According to the International Diabetes Federation (IDF), in 2017, 1 in 11 adults were suffering from diabetes across the globe. Similarly, consumption of antidiabetic drugs has increased considerably in Europe during recent years. Such factors will impel adults segmental share in forthcoming period.

Pediatric patient population segment will grow at 11.4% CAGR over the projected period. Number of diabetes cases among paediatric population are growing rapidly. Along with type 1 diabetes, that is majorly found in children, paediatric population suffering from type 2 diabetes is also significantly escalating. Additionally, implementation of several children programs for diabetes will support antidiabetics market growth over the foreseeable future.

Oral antidiabetics market contributed to largest revenue size of USD 39,714.7 million in 2017. Oral hypoglycaemics are widely used for T2DM patients. Newer drugs are largely being created by firms to be given through oral route for more efficacy as well as to overcome limitations of non-oral medications. Patients with T2DM are required to adopt oral medication within a couple of years post-diagnosis. Also, oral antidiabetics improve beta cell function indirectly while reducing glucotoxicity. Above benefits will assist oral antidiabetics segment growth during the forecast period.

Insulin pumps market will record highest CAGR of 11.3% during the projection timeframe. Insulin pump usage is recommended in patients having high resistance to insulin and weak glycaemic control. Insulin pumps prevent administration of multiple injections along with delivering high efficacy should escalate the customer preference. Availability of reimbursement in some countries will further accelerate demand for insulin pumps in the coming years.

Make an inquiry for purchasing this report @ https://www.gminsights.com/inquiry-before-buying/504

Antidiabetics industry witnessed the first commercially available medication in 1936 known as PZI (protamine zinc insulin). Nordisk followed the first drug development when NPH (neutral protamine Hagedorn) was released in Denmark by the company. Further innovations were made subsequently including lente series of insulin that was trailed by first approved rapid-acting human insulin in 1996. Recently, firms are focusing on breakthroughs in antidiabetics market that will further progress the innovations in antidiabetic drugs. In addition, expanding patient population across the world will largely contribute to rise in demand for antidiabetics, thereby augmenting antidiabetics industry growth in the foreseeable future.

Global Market Insights, Inc., headquartered in Delaware, U.S., is a global market research and consulting service provider; offering syndicated and custom research reports along with growth consulting services. Our business intelligence and industry research reports offer clients with penetrative insights and actionable market data specially designed and presented to aid strategic decision making. These exhaustive reports are designed via a proprietary research methodology and are available for key industries such as chemicals, advanced materials, technology, renewable energy and biotechnology.

Arun Hegde
Corporate Sales, USA
Global Market Insights, Inc.
Phone: 1-302-846-7766
Toll Free: 1-888-689-0688
Email: sales@gminsights.com
Web: https://www.gminsights.com
Blog: http://solutionrocket.com

This release was published on openPR.